Navigation Links
Advanced Life Sciences Announces Delisting From Nasdaq and Pending Quotation of its Common Stock on the OTC Bulletin Board
Date:5/4/2009

- Company Appeals Delisting Decision to Nasdaq Listing and Hearing Review Council -

CHICAGO, May 4 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS) announced today that the Nasdaq Listing Qualifications Panel (the "Panel") has determined to suspend trading in the Company's common stock from the Nasdaq Stock Market effective at the open of business on Tuesday, May 5, 2009. The Panel's decision was based on the Company's inability to evidence compliance with the $2.5 million shareholders' equity requirement or the $35 million market value of listed securities requirement. The Company requested that the Nasdaq Listing and Hearing Review Council (the "Listing Council") issue a stay on the Panel's decision to suspend the Company's common stock from trading but the Listing Council informed the Company today that it would not call the matter for review. The Company has formally appealed the decision to the Listing Council, which may affirm, modify, reverse, dismiss, or remand the decision.

The Company also announced that it has engaged a market maker that has filed a Form 211 application to quote the Company's common stock on the OTC Bulletin Board (OTCBB). The application is pending with Financial Industry Regulatory Authority (FINRA). Listing on the OTCBB will allow the Company to sell shares of common stock under its Standby Equity Distribution Agreement (SEDA) with YA Global Investments, L.P., an affiliate of Yorkville Advisors, which provides for the sale of up to $15.0 million of shares of the Company's common stock over a two-year commitment period. The Company's common stock will also be eligible for trading on the Pink Sheets beginning on Tuesday, May 5, 2009.

"While we are disappointed by Nasdaq's determination, we will continue to appeal the decision as the OTCBB begins quotation of our securities," stated Dr. Michael T. Flavin, chairman and chief executive officer of Advanced Life Sciences. "The Company has been current in its filings with the SEC and is preparing for a major corporate milestone in our upcoming FDA Advisory Committee meeting scheduled for June 2, 2009 to review the NDA for cethromycin as a treatment for community-acquired pneumonia. As we prepare for that event, we look forward to reestablishing the active market for our shares on the OTC Bulletin Board."

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. For more information, please visit us on the web at www.advancedlifesciences.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
3. Advanced Age No Bar to Liver Transplant
4. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
5. Advanced technologies aim to transform the coaching of top athletes
6. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
7. Advanced Life Sciences Joins NASDAQ Capital Market
8. Experimental drug shows promise in advanced kidney cancer
9. TCS Healthcare Technologies Announces Full Integration of Case Management Adherence Guidelines into Acuity Advanced Care(TM) System
10. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
(Date:6/24/2016)... ... 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ), ... official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the practice, ... says the decision to support the pageant in an official capacity is a ...
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology: